Completed Initial Public Offering Raising $86.3 Million in Gross ProceedsInitiated Enrollment in Multiple-Ascending Dose ...
Key Highlights: Top-line results from confirmatory Phase III study with TALICIA® for H. pylori ...
If approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in ...
